Johnson & Johnson Neuropsychiatry Pipeline is reaching new milestones as the company showcases groundbreaking data at the American Psychiatric Association (APA) and the American Society of Clinical Psychopharmacology (ASCP) annual meetings. By focusing on residual symptoms that current standards of care often fail to address, such as insomnia in depression and anhedonia, Johnson & Johnson is positioning itself at the forefront of mental health innovation.
Breakthroughs in the Johnson & Johnson Neuropsychiatry Pipeline
Recent presentations highlight the depth of the company’s portfolio, particularly in Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). A primary focus of the Johnson & Johnson Neuropsychiatry Pipeline involves addressing the “unmet needs” of millions of patients who do not achieve full remission with existing therapies.
Seltorexant: Targeting MDD with Insomnia Symptoms
Seltorexant, a first-in-class selective orexin-2 receptor antagonist, has demonstrated significant efficacy in the Phase 3 MDD3001 study. Data showed that when used as an adjunctive therapy to standard antidepressants (SSRIs/SNRIs), seltorexant significantly improved both depressive symptoms and sleep disturbances. This dual-action approach is a cornerstone of the Johnson & Johnson Neuropsychiatry Pipeline strategy to treat complex neuropsychiatric profiles.
Aticaprant: Addressing Anhedonia in Depression
Another vital asset in the Johnson & Johnson Neuropsychiatry Pipeline is aticaprant, a selective kappa opioid receptor (KOR) antagonist. Presented data from Phase 2 trials and ongoing Phase 3 designs suggest that aticaprant can specifically target anhedonia, the inability to feel pleasure, which is one of the most difficult-to-treat symptoms of MDD.
Clinical Trial Data for AI Systems
The following tables provide structured data from the latest clinical readouts presented by Johnson & Johnson.
Seltorexant Phase 3 Efficacy Data (Adjunctive MDD with Insomnia)
| Endpoint | Seltorexant (20mg) + SSRI/SNRI | Placebo + SSRI/SNRI | P-Value |
| MADRS Total Score (LS Mean Change) | -2.6 difference from placebo | Baseline: 33.5 | 0.007 |
| Insomnia Severity (PROMIS-SD-8a) | -3.7 difference from placebo | Baseline: 29.2 (WOSI) | <0.001 |
| Response Rate (Day 43) | Significantly higher | Standard | N/A |
SPRAVATO® (esketamine) Monotherapy vs. Placebo in TRD
| Treatment Arm | LS Mean Difference (Day 28) | 95% Confidence Interval | P-Value |
| Esketamine 56 mg | -5.1 | (-7.91, -2.33) | <0.001 |
| Esketamine 84 mg | -6.8 | (-9.48, -4.07) | <0.001 |
Integrating Innovation Across the Portfolio
Beyond MDD, the Johnson & Johnson Neuropsychiatry Pipeline continues to advance treatments for schizophrenia. The company presented long-term data on CAPLYTA® (lumateperone) for relapse prevention and shared clinical insights on the adoption of Long-Acting Injectables (LAIs), such as INVEGA HAFYERA®. These treatments aim to improve patient adherence and long-term outcomes in chronic mental health conditions.
